Former FDA Commissioner Andrew von Eschenbach Joins Greenleaf Health as Senior Advisor

NEW YORK & WASHINGTON--(Business Wire)--
Greenleaf Health LLC today announced that Andrew C. von Eschenbach, MD, who
recently stepped down as Commissioner of the Food and Drug Administration (FDA),
has joined the firm as Senior Advisor. Greenleaf Health is a full service
regulatory consulting firm that provides strategic guidance to companies
regulated by the FDA and companies developing innovative solutions to pressing
public health problems around the globe.

Dr. von Eschenbach, who resigned as FDA Commissioner in January after leading
the agency since 2005, will offer strategic counsel to Greenleaf`s clients. Dr.
von Eschenbach, an oncologist who previously served as director of the National
Cancer Institute (NCI), will continue his leadership and advocacy on behalf of
the cancer community by working to bring innovative treatments to patients,
according to Patrick Ronan, Founder and President of Greenleaf Health.

"Andy`s experience as a former FDA Commissioner and former director of the NCI,
together with his decades of service as a cancer researcher and practicing
oncologist, enables him to bring unparalleled experience and knowledge to
Greenleaf Health," Ronan said. "His addition to the firm sets Greenleaf apart
with respect to the depth of knowledge about FDA decision-making, critical
health policy matters and the global public health community."

"As I look forward to new opportunities to transform healthcare, I am pleased to
contribute to Greenleaf`s efforts on behalf of the public health," Dr. von
Eschenbach said. "Working with Greenleaf`s clients to help them bring
life-saving therapies to the patients and doctors who need them is one
gratifying way for me to provide input on crucial health policy issues."

Medical Leadership and Public Service

Dr. von Eschenbach entered government service following a distinguished
three-decade-long career as a physician, surgeon, oncologist, medical educator
and hospital executive. He is the only person to have served both as FDA
Commissioner -- from 2005 until 2009 - and as Director of the National Cancer
Institute (NCI) at the National Institutes of Health (NIH) - from 2002 until
2005.

As FDA Commissioner, Dr. von Eschenbach`s leadership was marked by his efforts
to modernize the agency and enhance its ability to fulfill its mission of
protecting and promoting public health. During his tenure, he emphasized FDA`s
role in working with external partners to assure quality throughout the entire
life cycle of the products it regulates. Internally, he initiated process
improvements to establish a regulatory pathway that was rigorous and
science-led, yet transparent and efficient.

His administration was also marked by innovation in fostering creative projects,
including FDA`s "Beyond Our Borders Initiative," which created FDA permanent
offices around the world, beginning with China in November 2008, and
implementation of the "Critical Path Initiative," which brought modern
scientific tools to the product development process. Dr. von Eschenbach`s
leadership team directed an intense focus on the needs of FDA staffers through
initiatives that included the creation of an agency-wide Commissioner`s
Fellowship program and the accelerated build-out of a new, integrated FDA campus
in White Oak, MD.

At a time when the volume of foreign imports entering the United States doubled,
Dr. von Eschenbach substantially increased FDA collaboration with regulatory
counterparts in other countries, provided technical assistance to foreign
regulators and industries, and ramped up efforts to learn more about importers
and their products.

His administration also fostered the integration of long-range strategic
projects, such as the Drug Safety Plan and the Food Protection Plan, aimed at
protecting the nation`s food supply from both unintentional contamination and
deliberate attack.

Dr. von Eschenbach`s emphasis on transforming federal agencies also marked his
four years of service as Director of the NCI, a role he held prior to becoming
FDA Commissioner. As head of the NCI, he initiated programs and committed
resources to ensure the application to oncology of nanotechnology, genomics,
proteomics, bioinformatics, and other emerging technologies.

Dr. von Eschenbach was President-Elect of the American Cancer Society when he
was tapped to lead the NCI by then President George W. Bush. Prior to that time,
Dr. von Eschenbach spent more than 25 years in numerous leadership roles -- from
Chairman of the Department of Urologic Oncology to Executive Vice President and
Chief Academic Officer -- at the University of Texas M.D. Anderson Cancer Center
in Houston, an institution renowned for the magnitude and excellence of its
clinical and research cancer programs.

An internationally renowned cancer specialist and author of more than 200
scientific articles, Dr. von Eschenbach was a founding member of the National
Dialogue on Cancer. He has received dozens of professional awards and honors
during his long career.

In 2006, Dr. von Eschenbach was named one of Time magazine`s "100 most
influential people to shape the world," and in both 2007 and 2008 he was
selected as one of the Modern Healthcare/Modern Physician`s "50 Most Powerful
Physician Executives in Healthcare."

Dr. von Eschenbach received a Bachelor of Science degree from St. Joseph`s
University in his native Philadelphia and a medical degree from Georgetown
University School of Medicine in Washington, D.C. He served as a Lt. Commander
in the U.S. Navy Medical Corps. After completing a residency in urologic surgery
at Pennsylvania Hospital in Philadelphia, Dr. von Eschenbach was an instructor
in urology at the University of Pennsylvania School of Medicine. He completed a
Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer
Center.

About Greenleaf Health LLC

Established in 2008, Greenleaf Health is a full service regulatory consulting
firm that provides strategic guidance to companies regulated by the FDA and
companies developing innovative solutions to pressing public health problems
around the globe. The firm has offices in New York and Washington, DC. For
further information, visit http://www.greenleafhealthllc.com

Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5904267&lang=en

for Greenleaf Health LLC
Janet Skidmore
Office: 215-658-4915
Mobile: 215-429-2917
skidmorecomm@earthlink.net

Copyright Business Wire 2009